PAI -1 INHIBITOR AS BIOMARKER OF CARDIORENAL DAMAGE

Danijela D. Tasić, Katarina S. Tasić

DOI Number
http://doi.org/10.22190/FUMB170525014T
First page
91
Last page
94

Abstract


Plasminogen activator inhibitor 1 (PAI-1), which belongs to the family of serine protease inhibitors  is the primary regulator of plasminogen activity. PAI-1 is synthesized as a single-chain glycopeptide and is deposited in the platelets in a latent form, from which it is released upon their activation. It is spontaneously converted into stable molecules, unless it reacts with proteins from the plasma. As a powerful inhibitor of fibrinolysis, it participates in the pathogenesis of endothelial damage, processes of accelerated atherosclerosis and thromboembolism. All the diseases of the cardiovascular system which are dominated by the processes of fibrosis and thrombosis lead to an increase in PAI-1 in the circulation. In the emergence and development of atherosclerosis, it plays a role not only in the formation of intraluminal thrombus but also in neointimal proliferation. PAI-1 is not normally present in kidney tissue, but its concentration increases significantly in its acute and chronic kidney disease, thanks to the synthesis by the intrarenally localized inflammatory cells. In addition to genetic predisposition, the factors that directly influence the production of PAI-1 are the following: glycemia, insulin and various neurohumoral factors. It is not normally present in the kidney tissue, but its intrarenal concentration increases significantly in acute and chronic kidney diseases. Numerous studies have confirmed the significant role of PAI-1 in the development of diabetes complications. During the last decade there has been a growth of interest in the introduction of non-invasive methods or biomarkers that would assess the degree of fibrosis in the kidney. Many studies have confirmed association between kidney and heart disease. It is not only that these diseases share common risk factors, but many other mechanisms have been suggested. Plasminogen activator inhibitor -1 plays a role in the pathogenesis of endothelial damage, processes of fibrosis and thrombosis, development of diabetes complications and acute and chronic kidney diseases.


Keywords

cardio-renal syndrome, biomarkers, plasminogen activator inhibitor-1

Full Text:

PDF

References


Jiang Q, Gingles NA, Olivier MA, Miles LA, Parmer JR. The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1(PAI-1), is targeted to and released from catecholamine storage vesicles. Blood 2011; 117:7155-7163.

Xu Z, Francis J, Ploplos C, Ploplis VA. Plasminogenactivator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood 2010; 115:2038-2204.

Ridker MP, Rifai N, Clearfield M, Downs JR, Weis ES, Miles S et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344(26):1959-1965.

Milijic P, Willemse J, Djordjevic V, Radojkovic D, Colovic M, Elezovic I, et al. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): A Molecular Link Between Coagulation and Fibrinolysis. Srp Arh Celok Lek 2010;138(1):74-78.

Van Hinsbergh WMV. Endothelium-role in regulation of coagulation and inflammation. Semin Thromb Hemost 2012; 34:93-106.

Flevaris P, Vaughan D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin Thromb Hemost 2017; 43(2):169-177.

Sharony R, Yu PJ, Park J, Galloway CA, Mignatti P, Pintucci G. Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflammat 2010; 7:2-17.

Miles LA, Parmer M, Pamer JR. PAI-1: Cardiac friend or foe? Blood 2010; 115:1862-1863.

Pretorius M, Donahue BS, Yu Ch, Greelish PJ, Roden DM, Brown NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 2007; 116(Suppl 1):1-7.

Hillenbrand A, Knippschild U, Weiss M, Schrezenmeier H, Henne-Bruns D, Huber-Lang M, et al. Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surgery 2010; 10:26.

Tasic D, Radenkovic S, Kocic G, Ilic Deljanin M, Ignjatovic A. Microinflammation Factors in the Common Diseases of Heart and Kidneys. Disease Markers 2015. Article ID 70589. http//dx.doi.org/10.1155/2015/470589.

Tasic D. Clinical modalities of the cardiorenal syndrome and the significance of certain biomarkers in its estimation [dissertation on the Internet]. Niš: Universitz of Niš, Faculty of Medicine; 2015. Available from: https://fedorani.ni.ac.rs/fedora/get/o:1027/bdef:Content/download [in Serbian]

Velickovic D, Djukic D, Tasic D. Nonsteroidal anti-inflammatory drugs and hypertension – does an exeption change the rule? Acta Medica Mediane 2014; 53(3): 25-31. doi:10.5633/amm.2014.0304

Devaraj S, Xy ZD, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107:398-404.

Zeisberg M, Neilson G. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21:1819-1834.

Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, et al. A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arterioscler Thromb Vasc Biol 2013; 33:935-942.

Fogo AB. Renal fibrosis: not just PAI-1 in the sky. J Clin Invest 2003; 112:326-328.




DOI: https://doi.org/10.22190/FUMB170525014T

Refbacks

  • There are currently no refbacks.


ISSN 0354-2017 (Print)

ISSN 2406-0526  (Online)